Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ira Gantz
A Randomized, Placebo- And Sitagliptin-Controlled Trial of the Safety and Efficacy of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients With Type 2 Diabetes
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Melanocortin Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
IUPHAR/BPS Guide to Pharmacology CITE
Related publications
Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients With Type 2 Diabetes: The EDIT Randomized Trial
PLoS ONE
Multidisciplinary
Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Efficacy and Safety of Repaglinide Added to Sitagliptin in Japanese Patients With Type 2 Diabetes: A Randomized 24-Week Open-Label Clinical Trial
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial
The Lancet Diabetes and Endocrinology
Internal Medicine
Endocrinology
Metabolism
Diabetes
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients With Type 2 Diabetes Mellitus
Global Journal of Endocrinological Metabolism
Combination Therapy With Once-Weekly Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Case Series
Pharmacy Practice
Pharmaceutical Science
Pharmacy
Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Frontiers in Pharmacology
Pharmacology
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes